Silence Therapeutics (NASDAQ:SLN) Price Target Cut to $25.00 by Analysts at Morgan Stanley

Silence Therapeutics (NASDAQ:SLN) had its price target trimmed by Morgan Stanley from $45.00 to $25.00 in a research note released on Friday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other analysts also recently weighed in on SLN. HC Wainwright reissued a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Friday, March 7th. Chardan Capital decreased their price target on Silence Therapeutics from $55.00 to $35.00 and set a “buy” rating for the company in a report on Friday. The Goldman Sachs Group cut their target price on Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating on the stock in a research report on Tuesday, March 4th. Finally, BMO Capital Markets lowered their target price on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $33.83.

Silence Therapeutics Trading Up 3.9 %

Silence Therapeutics stock opened at $3.70 on Friday. The stock has a 50-day moving average price of $3.39 and a two-hundred day moving average price of $6.57. Silence Therapeutics has a 12 month low of $1.97 and a 12 month high of $24.38. The company has a market capitalization of $110.74 million, a PE ratio of -2.36 and a beta of 1.20.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.42). The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $3.58 million. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. As a group, analysts predict that Silence Therapeutics will post -1.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Redmile Group LLC grew its position in Silence Therapeutics by 26.3% in the 4th quarter. Redmile Group LLC now owns 2,399,317 shares of the company’s stock valued at $16,507,000 after purchasing an additional 500,000 shares during the period. Nantahala Capital Management LLC increased its position in shares of Silence Therapeutics by 424.8% during the fourth quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company’s stock worth $7,222,000 after acquiring an additional 849,676 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of Silence Therapeutics by 35.3% during the fourth quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company’s stock worth $4,356,000 after acquiring an additional 165,300 shares in the last quarter. Cantor Fitzgerald L. P. raised its holdings in shares of Silence Therapeutics by 61.5% in the 4th quarter. Cantor Fitzgerald L. P. now owns 539,726 shares of the company’s stock worth $3,713,000 after acquiring an additional 205,534 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Silence Therapeutics by 48,165.6% in the 4th quarter. Bank of America Corp DE now owns 499,066 shares of the company’s stock valued at $3,434,000 after acquiring an additional 498,032 shares in the last quarter. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.